Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis

E. N. van Roon; T. L.Th.A. Jansen; M. A.F.J. van de Laar; M. Janssen; J.P. Yska; R. Keuper; P. M. Houtman; J. R.B.J. Brouwers

doi:10.1136/ard.2004.025205

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Archive
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Article Text

other Versions

You are currently viewing an earlier version of this article (January 09, 2022).
View the most recent version of this article

Extended Report

Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis

https://doi.org/10.1136/ard.2004.025205

Statistics from Altmetric.com

This is a PDF-only article. The first page of the PDF of this article appears above.

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Statistics from Altmetric.com

Read the full text or download the PDF:

Log in using your username and password

Read the full text or download the PDF:

Log in using your username and password